Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xencor, Inc. - Common Stock
(NQ:
XNCR
)
19.75
-0.11 (-0.53%)
Streaming Delayed Price
Updated: 9:45 AM EDT, Jul 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xencor, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
July 17, 2026
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2026 Financial Results
May 06, 2026
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
May 04, 2026
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
March 04, 2026
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
From
Xencor, Inc.
Via
Business Wire
Xencor to Participate at Upcoming Investor Conferences
February 23, 2026
From
Xencor, Inc.
Via
Business Wire
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
January 08, 2026
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
December 09, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor to Participate at Upcoming Investor Conferences
November 10, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
October 24, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
October 21, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor to Participate at Upcoming Investor Conferences
August 27, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Second Quarter 2025 Financial Results
August 06, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
July 31, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2025 Financial Results
May 07, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
April 29, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Todd Simpson to Board of Directors
March 13, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor to Participate at Upcoming Investor Conferences
November 26, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
November 04, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
October 10, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Upcoming Change to Board of Directors
October 04, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 12, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
September 11, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Proposed Public Offering of Common Stock
September 10, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
September 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
September 06, 2024
From
Xencor, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
